Compile Data Set for Download or QSAR
Report error Found 78 Enz. Inhib. hit(s) with all data for entry = 1067
TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306718BDBM306718(US10149839, Example 4 | N-(2-(3,5-difluoro-4-((1R,...)
Affinity DataIC50: 0.200nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306726BDBM306726(US10149839, Example 12 | N-(2-(4- ((1R,3R)-2- (2,2...)
Affinity DataIC50: 0.910nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306783BDBM306783(US10149839, Example 69 | 2,2-difluoro-3- ((1S,3R)-...)
Affinity DataIC50: 0.970nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306785BDBM306785(US10149839, Example 71 | N1-(5- ((1S,3R)-2- (2,2- ...)
Affinity DataIC50: 1nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306719BDBM306719(US10149839, Example 5 | N-(2-(3,5-difluoro-4-((1R,...)
Affinity DataIC50: 1.10nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306736BDBM306736(US10149839, Example 22 | 3-fluoro-N-(2- (3-fluoro-...)
Affinity DataIC50: 1.10nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306724BDBM306724(US10149839, Example 10 | 3-((1R,3R)-1-(2,6-difluor...)
Affinity DataIC50: 1.10nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306717BDBM306717(US10149839, Example 3 | N-(2-(3,5-difluoro-4-((1R,...)
Affinity DataIC50: 1.10nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306760BDBM306760(US10149839, Example 46 | 3-((1R,3R)-1-(2,6-difluor...)
Affinity DataIC50: 1.20nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306784BDBM306784(US10149839, Example 70 | N-(2-((5- ((1S,3R)-2- (2,...)
Affinity DataIC50: 1.20nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306778BDBM306778(US10149839, Example 64 | 2,2-difluoro-3- ((1R,3R)-...)
Affinity DataIC50: 1.20nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306722BDBM306722(US10149839, Example 8 | 3-fluoro-N-(2-(4-((1R,3R)-...)
Affinity DataIC50: 1.20nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306756BDBM306756(US10149839, Example 42 | N-(2-((5-((1R,3R)-2-(2,2-...)
Affinity DataIC50: 1.20nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306739BDBM306739(N-(2-(4- ((1R,3R)-2- (2,3-difluoro- propyl)- 3-met...)
Affinity DataIC50: 1.20nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306720BDBM306720(US10149839, Example 6 | N-(2-(3,5-difluoro-4-((1R,...)
Affinity DataIC50: 1.30nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306744BDBM306744(US10149839, Example 30 | (1S,3R)-1-(5-bromopyridin...)
Affinity DataIC50: 1.30nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306731BDBM306731(US10149839, Example 17 | BDBM306732 | 3-((1R,3R)-1...)
Affinity DataIC50: 1.40nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306762BDBM306762(US10149839, Example 48 | N-(2-(4-((1R,3R)-2-(2,2-d...)
Affinity DataIC50: 1.5nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306755BDBM306755(US10149839, Example 41 | 3-Fluoro-N-(2-((4-methoxy...)
Affinity DataIC50: 1.5nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306768BDBM306768(US10149839, Example 54 | N1-(4- ((1R,3R)-2- (2,2- ...)
Affinity DataIC50: 1.60nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306769BDBM306769(US10149839, Example 55 | N-(2-(4- ((1R,3R)-2- (2,2...)
Affinity DataIC50: 1.60nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306772BDBM306772(US10149839, Example 58 | 2,2-difluoro-3- ((1R,3R)-...)
Affinity DataIC50: 1.60nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306729BDBM306729(BDBM306730 | US10149839, Example 15 | N-(2-(4- ((1...)
Affinity DataIC50: 1.70nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306754BDBM306754(US10149839, Example 40 | N-(2-((5-((1R,3R)-2-(2,2-...)
Affinity DataIC50: 1.70nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306734BDBM306734(3-(3,5- difluoro-4- ((1R,3R)-2-(2- fluoro-2-methyl...)
Affinity DataIC50: 1.80nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306757BDBM306757(US10149839, Example 43 | N-(2-(4-((1R,3R)-2-(2,2-D...)
Affinity DataIC50: 1.80nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306749BDBM306749(US10149839, Example 35 | (5-bromo-3-methoxypyridin...)
Affinity DataIC50: 1.80nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306752BDBM306752(US10149839, Example 38 | 5-chloropyrazine-2-carbal...)
Affinity DataIC50: 1.90nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306770BDBM306770(US10149839, Example 56 | N-(2-(4- ((1R,3R)-2- (2,2...)
Affinity DataIC50: 2nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306788BDBM306788(US10149839, Example 74 | N-(2-(4- ((1R,3R)-2- (2,2...)
Affinity DataIC50: 2nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306791BDBM306791(US10149839, Example 77 | N-(2-((5- ((1R,3R)-2- (2,...)
Affinity DataIC50: 2.10nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306721BDBM306721(US10149839, Example 7 | 3-fluoro-N-(2-((5-((1R,3R)...)
Affinity DataIC50: 2.10nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306763BDBM306763(US10149839, Example 49 | N1-(4-((1R,3R)-2-(2,2-dif...)
Affinity DataIC50: 2.10nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306734BDBM306734(3-(3,5- difluoro-4- ((1R,3R)-2-(2- fluoro-2-methyl...)
Affinity DataIC50: 2.20nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306739BDBM306739(N-(2-(4- ((1R,3R)-2- (2,3-difluoro- propyl)- 3-met...)
Affinity DataIC50: 2.20nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306741BDBM306741(US10149839, Example 27 | 3-fluoro-N- ((S)-1-(4- ((...)
Affinity DataIC50: 2.20nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306750BDBM306750(US10149839, Example 36 | (6-chloro-4-methoxypyridi...)
Affinity DataIC50: 2.30nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306764BDBM306764(BDBM306765 | N-(2-(3,5- difluoro-4- ((1R,3R)-2-(2-...)
Affinity DataIC50: 2.30nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306731BDBM306731(US10149839, Example 17 | BDBM306732 | 3-((1R,3R)-1...)
Affinity DataIC50: 2.30nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306727BDBM306727(US10149839, Example 13 | N-(2-(4- ((1R,3R)-2- (2,2...)
Affinity DataIC50: 2.40nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306751BDBM306751(US10149839, Example 37 | 3-fluoro-N-(2- ((5-((1R,3...)
Affinity DataIC50: 2.40nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306786BDBM306786(US10149839, Example 72 | N-(2-(3,5- difluoro-4- ((...)
Affinity DataIC50: 2.40nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306779BDBM306779(US10149839, Example 65 | 2,2-difluoro-3- ((1R,3R)-...)
Affinity DataIC50: 2.40nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306758BDBM306758(US10149839, Example 44 | N1-(3,5-difluoro-4-((1R,3...)
Affinity DataIC50: 2.5nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306728BDBM306728(US10149839, Example 14 | N-(2-(4- ((1R,3R)-2- (2,2...)
Affinity DataIC50: 2.5nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306729BDBM306729(BDBM306730 | US10149839, Example 15 | N-(2-(4- ((1...)
Affinity DataIC50: 2.5nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306747BDBM306747(US10149839, Example 33 | 3-fluoro-N-(2- ((5-((1R,3...)
Affinity DataIC50: 2.5nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306781BDBM306781(US10149839, Example 67 | N1-(5- ((1R,3R)-2- (2,2- ...)
Affinity DataIC50: 2.5nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306733BDBM306733(US10149839, Example 19 | 2-(3,5- difluoro-4- ((1R,...)
Affinity DataIC50: 2.5nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetEstrogen receptor(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 306782BDBM306782(US10149839, Example 68 | N1-(5- ((1R,3R)-2- (2,2-d...)
Affinity DataIC50: 2.60nMAssay Description:Compounds were dosed directly from a compound source microplate containing serially diluted compound (4 wells containing 10 mM, 0.1 mM, 1 mM and 10 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

Displayed 1 to 50 (of 78 total ) | Next | Last >>
Jump to: